Sickle Cell Disease Treatment Market, By Disease (Sickle Cell Anaemia, Sickle Haemoglobin C Disease, Sickle Beta Thalassemia, Others), By Treatment (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant), By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Sickle Cell Disease Treatment Market size was valued at USD 3,010.7 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.
Hemoglobin, a protein that transports oxygen throughout the body, is impacted by sickle cell disease (SCD), a hereditary red blood cell (RBC) problem. Numerous consequences are brought on by it, including acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). Currently, doctors frequently recommend bone marrow and blood transplants to treat SCD. It entails removing the damaged bone marrow and replacing it with healthy bone marrow obtained from a donor. As they can lessen particular symptoms and extend patients\' lives, other efficient therapies including pharmaceuticals and blood transfusions are also being used.
Sickle Cell Disease Treatment Market- Market Dynamics
- Innovation in novel medication drives the market growth
The first new treatment for sickle cell disease in 20 years has been discovered in the United Kingdom. Crizanlizumab, a drug produced by Novartis, has been referred to be \"an innovative treatment.\" According to the BBC, it is injected into a vein and can be used alone or in conjunction with regular blood transfusions and conventional medical care. In a study, patients using crizanlizumab experienced a sickle-cell crisis 1.6 times year on average, down from nearly three times annually in the norm. A drug called crizanlizumab is used to reduce the incidence of vaso-occlusive crises in sickle cell anemia patients aged 16 and older. The Sickle Cell Disease Treatment Market is expanding as a result of these inventive breakthrough treatments.
Sickle Cell Disease Treatment Market- Key Insights
- As per the analysis shared by our research analyst, the global Sickle Cell Disease Treatment market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)
- The Sickle Cell Disease Treatment industry is projected to grow at a significant rate owing to the high incidence of sickle cell anemia disease
- Based on the disease, the sickle cell anaemia segment is expected to grow at the highest CAGR over the forecast period
- Based on the treatment, the blood transfusion segment is expected to capture the largest market share over the forecast period
- Based on region, North America is expected to dominate the market over the forecast period
Sickle Cell Disease Treatment Market- Segmentation Analysis:
The Global Sickle Cell Disease Treatment Market is segmented based on disease, treatment, and Region.
Based on disease, the global Sickle Cell Disease Treatment market is segmented into sickle cell anaemia, sickle haemoglobin c disease, sickle beta thalassemia, others. The sickle cell anaemia segment is expected to grow at the highest CAGR over the forecast period. This expansion is the result of an increase in sickle cell anemia patients brought on by a gene mutation. A mutation in the haemoglobin-Beta gene found on chromosome 11 causes sickle cell disease. Red blood cells in sickle cell anemia are hard, sticky, and malformed as a result of the defective hemoglobin. The prevalence of inheriting sickle cell anemia is accelerating this market\'s expansion.
Based on treatment, the global market is segmented into blood transfusion, pharmacotherapy, bone marrow transplant. The blood transfusion segment is expected to capture the largest market share over the forecast period. The massive use of blood transfusion in the treatment of sickle cell disease is the cause of this rise. Acute chest syndrome (ACS) is treated with both simple transfusion (ST) of packed red blood cells and automated red cell exchange (RCE). The increasing use of blood transfusions in the treatment of stroke, which sickle cell disease patients commonly have, is fueling this market\'s expansion.
Sickle Cell Disease Treatment Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. The region\'s market revenue growth is primarily being driven by significant advancements in the treatment of sickle cell disease and widespread accessibility to treatment options. The high level of disposable income in this region is also a major driver of the expansion of market revenue. The highest revenue share came from the U.S. market as a result of rising government assistance. Additionally, local market players are joining forces and making acquisitions to diversify their product offerings and establish a worldwide presence. For instance, in 2022, Pfizer Inc. and Global Blood Therapeutics, Inc. reached a deal that will ultimately increase the hematology product portfolio.
Sickle Cell Disease Treatment Market- Competitive Landscape:
The key players operating in the market are Medunik USA, Bristol Myers Squibb Co., Emmaus Medical Inc., Addmedica, Novartis AG, Global Blood Therapeutics Inc, Sanofi SA, Bluebird Biotechnology, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics Inc., Editas Medicine Inc. and CRISPR Therapeutic.
Recent Developments:
- In February 2022, Global Blood Therapeutics Inc. was granted permission to sell Oxbryta for the treatment of sickle cell disease (SCD)-related hemolytic anemia in adults and children 12 years of age and older as a monotherapy or in combination with hydroxycarbamide.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET KEY PLAYERS
- Medunik USA
- Bristol Myers Squibb Co.
- Emmaus Medical Inc.
- Addmedica
- Novartis AG
- Global Blood Therapeutics Inc.
- Sanofi SA
- Bluebird Biotechnology
- Pfizer Inc.
- Aruvant Sciences Inc.
- Glycomimetics Inc.
- Editas Medicine Inc.
- CRISPR Therapeutic
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DISEASE
- Sickle Cell Anaemia
- Sickle Haemoglobin C Disease
- Sickle Beta Thalassemia
- Others
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TREATMENT
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Sickle Cell Disease Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Sickle Cell Disease Treatment Market Snippet by Disease
2.1.2. Sickle Cell Disease Treatment Market Snippet by Treatment
2.1.3. Sickle Cell Disease Treatment Market Snippet by Country
2.1.4. Sickle Cell Disease Treatment Market Snippet by Region
2.2. Competitive Insights
3. Sickle Cell Disease Treatment Key Market Trends
3.1. Sickle Cell Disease Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Sickle Cell Disease Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Sickle Cell Disease Treatment Market Opportunities
3.4. Sickle Cell Disease Treatment Market Future Trends
4. Sickle Cell Disease Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Sickle Cell Disease Treatment Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Sickle Cell Disease Treatment Market Landscape
6.1. Sickle Cell Disease Treatment Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Sickle Cell Disease Treatment Market – By Disease
7.1. Overview
7.1.1. Segment Share Analysis, By Disease, 2022 & 2030 (%)
7.1.2. Sickle Cell Anaemia
7.1.3. Sickle Haemoglobin C Disease
7.1.4. Sickle Beta Thalassemia
7.1.5. Others
8. Sickle Cell Disease Treatment Market – By Treatment
8.1. Overview
8.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
8.1.2. Blood Transfusion
8.1.3. Pharmacotherapy
8.1.4. Bone Marrow Transplant
9. Sickle Cell Disease Treatment Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
9.2. North America
9.2.1. Overview
9.2.2. Sickle Cell Disease Treatment Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.2.4. North America Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Sickle Cell Disease Treatment Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.7. Italy
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.7.3. Italy Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.7.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.8. United Kingdom
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.8.3. United Kingdom Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.8.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.9. France
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.9.3. France Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.9.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.10. Russia
9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.10.2. Russia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.10.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.11. Netherlands
9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.11.2. Netherlands Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.11.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.12. Sweden
9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.12.2. Sweden Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.12.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.13. Poland
9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.13.2. Poland Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.13.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.3.14. Rest of Europe
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.14.3. Rest of the Europe Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.3.14.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Sickle Cell Disease Treatment Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.6. India
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.6.3. India Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.6.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.7.3. China Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.7.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.8.3. Japan Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.8.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.9.3. South Korea Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.9.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.11. Thailand
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.11.3. Thailand Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.11.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.12. Indonesia
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.12.3. Indonesia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.12.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Sickle Cell Disease Treatment Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Sickle Cell Disease Treatment Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.7. United Arab Emirates
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.7.3. United Arab Emirates Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.7.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10. Key Vendor Analysis- Sickle Cell Disease Treatment Industry
10.1. Competitive Dashboard
10.2. Company Profiles
10.2.1. Medunik USA
10.2.2. Bristol Myers Squibb Co.
10.2.3. Emmaus Medical Inc.
10.2.4. Addmedica
10.2.5. Novartis AG
10.2.6. Global Blood Therapeutics Inc.
10.2.7. Sanofi SA
10.2.8. Bluebird Biotechnology
10.2.9. Pfizer Inc.
10.2.10. Aruvant Sciences Inc.
10.2.11. Glycomimetics Inc.
10.2.12. Editas Medicine Inc.
10.2.13. CRISPR Therapeutic
11. 360 Degree Analyst View
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
